Eads & Heald Wealth Management Sells 30 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Eads & Heald Wealth Management lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,040 shares of the medical research company’s stock after selling 30 shares during the quarter. Thermo Fisher Scientific comprises about 1.3% of Eads & Heald Wealth Management’s investment portfolio, making the stock its 21st largest holding. Eads & Heald Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,675,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Donaldson Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 10.2% during the fourth quarter. Donaldson Capital Management LLC now owns 5,721 shares of the medical research company’s stock worth $3,037,000 after buying an additional 531 shares during the last quarter. Flputnam Investment Management Co. lifted its holdings in shares of Thermo Fisher Scientific by 4.1% during the 4th quarter. Flputnam Investment Management Co. now owns 36,158 shares of the medical research company’s stock valued at $19,192,000 after purchasing an additional 1,413 shares in the last quarter. Keel Point LLC lifted its holdings in shares of Thermo Fisher Scientific by 17.6% during the 4th quarter. Keel Point LLC now owns 8,295 shares of the medical research company’s stock valued at $4,403,000 after purchasing an additional 1,243 shares in the last quarter. Sentry Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 32.0% during the 4th quarter. Sentry Investment Management LLC now owns 2,959 shares of the medical research company’s stock valued at $1,571,000 after purchasing an additional 718 shares in the last quarter. Finally, Bison Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 24.1% during the 4th quarter. Bison Wealth LLC now owns 1,816 shares of the medical research company’s stock valued at $964,000 after purchasing an additional 353 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. HSBC began coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price on the stock. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Finally, Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $601.56.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $7.36 during midday trading on Monday, hitting $557.87. 1,031,012 shares of the company’s stock were exchanged, compared to its average volume of 1,546,595. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company’s 50 day moving average price is $571.66 and its 200 day moving average price is $526.14. The firm has a market capitalization of $212.94 billion, a PE ratio of 36.11, a price-to-earnings-growth ratio of 2.38 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.40 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 10.10%.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last ninety days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.